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Abstract
The association between folic acid supplementation and birth defects other than neural tube defects (NTD) remains unclear. We used a
log-binomial regression model to investigate if periconceptional folic acid and/or multivitamin use was associated with birth defects in
Norway with prospectively collected data from the Medical Birth Registry of Norway (MBRN) during 1999–2013. We used the European
Surveillance of Congenital Anomalies (EUROCAT) classification system to define eleven organ-specific major birth defect groups (nervous sys-
tem, eye, ear–face–neck, cardiovascular system, respiratory system, oral clefts, digestive system, abdominal wall, urinary system, genital organs
and limb), with additional subgroups. Fetuses or infants whose mothers used folic acid and/or multivitamin supplements before and during
pregnancy were classified as exposed. During the years 1999–2013, 888 294 (99·0 %) live-born infants, 6633 (0·7 %) stillborn infants and
2135 (0·2 %) fetuses from terminated pregnancies due to fetal anomalies were registered in the MBRN. Among the live- and stillborn infants
of women who used vitamin supplements compared with infants of non-users, the adjusted relative risk (aRR) was 0·94 (95 % CI 0·91,
0·98) for total birth defects (n 18 382). Supplement use was associated with reduced risk of abdominal wall defects (aRR 0·58; 95 % CI 0·42,
0·80, n 377), genital organ defects (aRR 0·81; 95 % CI 0·72, 0·91, n 2299) and limb defects (aRR 0·81; 95 % CI 0·74, 0·90, n 3409). Protective
associations were also suggested for NTD, respiratory system defects and digestive system defects although CI included the null value of 1.
During the full study period, statistically significant associations between supplement use and defects in the eye, ear–face–neck, heart or oral
clefts were not observed.
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According to the WHO, globally more than 300 000 deaths
during the first 28 d of life were attributable to birth defects in
2015, with neural tube defects (NTD) being one of the most
serious of these defects(1). Also in 2015, the Global Burden of
Disease ranked birth defects as the number 5 cause globally
of deaths under the age of 5 years, an increase from number 7
in 1990(2). Deaths caused by birth defects most often occur early
in life, and thus the burden of years of life lost due to premature
mortality is severe(2,3). Micronutrient requirements increase sub-
stantially throughout pregnancy but are especially important
during the first trimester when organogenesis mainly occurs(4).
Nutritional status pre- and post-conception affects the growth
and development of the fetus, and deficiencies increase the risk
of birth defects(5). Folate deficiency is one of the most common
micronutrient deficiencies amongwomen in reproductive age(4),
along with Fe(6), iodine(7) and vitamin D(8) in the Nordic coun-
tries. In Norway, intake of dietary folate(9,10) and folic acid
supplements(11) is low. In the early 1990s, two randomised
controlled studies demonstrated that periconceptional folic acid
supplementation prevented the recurrence and occurrence of
NTD(12,13). Because of these studies, many authorities worldwide
implemented policies to fortify flour with folic acid, starting
in the USA from 1998(14). To date, more than sixty countries have
mandatory folic acid fortification programmes(15). In Norway,
there is no mandatory folic acid fortification and women plan-
ning to conceive have since 1998 been advised to take a daily
Abbreviations: aRR, adjusted relative risk; EUROCAT, European Surveillance of Congenital Anomalies; IVF, in vitro fertilisation; MBRN, Medical Birth Registry of
Norway; NTD, neural tube defect; RR, relative risk; TOPFA, termination of pregnancies due to fetal anomaly.
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supplement of 0·4mg folic acid from 1month before conception
and until the 12th week of gestation to reduce the risk of NTD(16).
Several observational studies and randomised controlled trials
have explored the associations of folic acid and multivitamins
with other birth defects, such as congenital heart defects(17), limb
reduction defects(18), urinary tract defects, as well as other
structural developmental anomalies(17). However, the literature
is inconclusive(19,20), and the role of folate remains unclear for
birth defects other than NTD. To our knowledge, associations
between folic acid supplements and major birth defect catego-
ries have not previously been investigated in nationwide cohorts
in the Nordic countries.
We conducted a prospective study using data from the
nationwide, population-based Medical Birth Registry of
Norway (MBRN) in the period 1999–2013. First, we investigated
the prevalence of birth defects among all births, including live
births, stillbirths and termination of pregnancies due to fetal
anomaly (TOPFA). Second, as our main objective, we compared
the risks of organ-specificmajor birth defects in live- and stillborn




The MBRN contains data on all live births and stillbirths in
Norway from 16 weeks’ gestation onwards since 1967. From
1999, information on women’s use of folic acid and multivitamin
supplements before and during pregnancy has been included,
along with smoking habits and ultrasound dating. Notification
of births is compulsory and includes information on the parents
(e.g. socio-demographic markers, maternal health status before
and during pregnancy, maternal smoking and use of folic
acid/multivitamins and medication), the delivery (e.g. operative
vaginal delivery, caesarean section, complications during
delivery) and the condition of the infant (e.g. plurality, birth
weight, gestational age, birth defects, neonatal diseases). Data
are collected during pregnancy and completed after delivery
by the attending midwife, and during the stay at the delivery unit
until discharge. Additionally, the MBRN also receives notifica-
tions from the neonatal intensive care units for all infants trans-
ferred to such units after birth. This routine has been in place
since 1999 and has improved the registration of birth defects.
Also from 1999, all TOPFA have routinely been added to the birth
registry to increase the ascertainment of birth defects. The
present study used data from the MBRN for the years 1999–2013.
Ethical statement
The present study was approved by the regional Medical Ethics
Committee of Western Norway, REK 2010/3310/REK vest.
Classification of birth defects
All infants in Norway undergo a paediatric examination at the
maternity ward before discharge or at the neonatal ward if the
child is transferred to such units after birth. Birth defects were
coded by the International Classification of Diseases-10 and
the International Classification of Diseases-10-British Pediatric
Association (addition by the British Pediatric Association). We
used the European Surveillance of Congenital Anomalies
(EUROCAT) classification system to define eleven organ-specific
major birth defect categories (subtypes in parentheses)(21). These
categories were nervous system (NTD), eye, ear–face–neck,
cardiovascular system (severe cardiovascular defects), respira-
tory system, oral clefts, digestive system (oesophageal atresia
with or without tracheaoesophageal fistula; anorectal atresia and
stenosis; other digestive defects), abdominal wall (gastroschisis;
omphalocele), urinary system (hydronephrosis; remaining
urinary defects), genital organs (hypospadias) and limb (limb
reduction defects; talipes equinovarus; polydactyly; syndactyly)
(online Supplementary Table S1). In the present study, we
excluded individuals with teratogenic syndromes, chromosomal
anomalies, and genetic syndromes and microdeletions (n 1747)
because major birth defects associated with these groups in most
cases have known causes unrelated to the exposure(21) (Fig. 1).
Very few hip anomalies are recognised as birth defects,
and hip anomalies were thus not counted as cases (online
Supplementary Table S1 for International Classification of
Fig. 1. Study population. TOPFA, termination of pregnancies due to fetal anomaly.
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Diseases codes). Births with multiple NTD were classified
according to the most severe defect; for example, anencephaly
accompanied with encephalocele or spina bifida was coded as
anencephaly, and encephalocele with spina bifida was coded
as encephalocele. Cases with one or more birth defect(s) within
the same organ-specific group were classified as isolated if
other organs were unaffected. In keeping with the EUROCAT
definition, sequences were assigned to the primary anomaly,
for example, clubfoot or pulmonary hypoplasia associated with
bilateral renal agenesis was classified as isolated bilateral renal
agenesis, andoral cleft associatedwith anencephalywas classified
as isolated anencephaly(22). Multiple births differ from single births
regarding birth defects(23), and therefore,we ran separate analyses
with singletons. However, our main analyses included singletons
and multiple births.
Folic acid and multivitamin supplementation
Information on supplement use is collected during pregnancy
and transferred to the birth notification form, where it is
registered into the following four checkboxes: ‘Folic acid before
pregnancy’, ‘Folic acid during pregnancy’, ‘Multivitamins before
pregnancy’ and ‘Multivitamins during pregnancy’. The data
that were available to us only had information on these four
checkboxes (multivitamin and/or folic acid before and/or during
pregnancy), without a specific option for those who had not
used supplements (one checkbox for ‘no use’). By default, all
those who had not reported use were therefore set to non-users.
No use of supplements (folic acid or multivitamins) at any time
was used as the reference group in all analyses (all of the four
checkboxes left unmarked). Infants, where the mother used
supplements (folic acid and/or multivitamins) before and during
pregnancy,were classified as exposed. This also included infants
where mothers only used supplements before pregnancy
(1·1 %). The exposure variable had the following categories:
no supplement use, supplement use before and during preg-
nancy or only before and supplement use during pregnancy
only. In order to study use of folic acid separately from use of
multivitamins, or the two of them combined, we created three
subcategories: use of multivitamins only (before and during
pregnancy), use of folic acid only (before and during pregnancy)
and use of both folic acid and multivitamins (before and during
pregnancy). Folic acid tablets available over the counter in
Norway during the study period contained 0·4 mg of folic acid,
while the maximum limit of folic acid in multivitamins was
0·2 mg(24).
Although the MBRN registers birth defects in terminated
pregnancies, spontaneous abortions from 16 gestational weeks,
and still- and live births from 22 gestational weeks, information
on supplement use has not been registered for TOPFA.
Consequently, our main analyses focused on the relation
between vitamin supplementation and birth defects among live
births and stillbirths from 16 gestational weeks.
Statistical analyses
We used a log-binomial regression model to calculate the
relative risks (RR) with 95 % CI for the relationship between
maternal periconceptional use of supplements and the risk of
infant birth defects, with the infant as the observation unit. To
account for non-independent data, we performed clustered
regression analyses using mothers’ identification number as
the cluster variable in all analyses.We also explored stratification
of the study sample by year of birth (1999–2005 v. 2006–2013).
The adjusted relative risk (aRR) models accounted for a priori
selected potential confounders, including year of birth,
maternal age (<20, 20–24 (reference), 25–29, 30–34, 35–39,
≥40 years), marital status (married (reference), cohabiting,
single, other), parity (0 (reference), 1, ≥2 previous births),
maternal smoking habits at the beginning of pregnancy
(non-smoker (reference), occasional smoker, daily smoker,
missing data), pregestational diabetes (no (reference), yes)
and maternal epilepsy (no (reference), yes). RR were reported
with and without adjustment for these potential confounders.
In a sensitivity analysis, we assessed multiple gestations and
in vitro fertilisation (IVF) related to supplement use and birth
defects. All analyses were performed using Stata version 16.0
(StataCorp).
Results
During the years 1999–2013, 888 294 (99·0 %) live-born infants,
6633 (0·7 %) stillborn infants and 2135 (0·2 %) TOPFA were
registered in the MBRN (Fig. 1). Table 1 shows the distributions
of birth defects among live births, stillbirths and terminated
pregnancies (n 20 517). Among live-born, stillborn and TOPFA,
heart defects were the most common subtype of birth defects
(85·6/10 000) followed by birth defects in the limbs (40·6/10 000),
the genital organs (25·9/10 000), urinary system (24·3/10 000),
nervous system (17·9/10 000), oral clefts (17·8/10 000), digestive
system (14·5/10 000), respiratory system (6·3/10 000), abdominal
wall system (5·7/10 000), eye (2·7/10 000) and ear–face–neck
(2·4/10 000). Among non-syndromic fetuses with birth defects,
the percentage of TOPFA was highest for those with NTD
(67·1 %), nervous system defects in general (51·4%) and ompha-
locele (37·2%). In contrast, the percentage of TOPFA was lowest
for those with genital defects (1·2%), oral clefts (2·4%), eye
defects (4·1%) and heart defects (4·4%).
Table 2 shows maternal characteristics for 894 927 live- and
stillborn infants according to folic acid and/or multivitamin
supplement use before and/or during pregnancy. Mean mater-
nal age at delivery was 29·6 years (SD 5·2, range 13–55 years,
data not shown in table). About 42 % were first-time mothers,
and more than 90 % of the women were married or cohabiting.
Nearly 14 % of the women smoked at the beginning of
pregnancy, with a decreasing prevalence over the study period
from 22·5 to 6·9 %. Smoking information was missing in more
than 16 % of the women overall. The proportion of women
with pregestational diabetes and epilepsy was both 0·7 %.
During 1999–2013, there was a 3-fold increase in reported
supplement use before and during pregnancy from 9·0 to
27·1 %, and more than a 2-fold increase for use during preg-
nancy only, from 19·5 to 48·6 %. Use of folic acid supplements
before and during pregnancy was associated with higher
maternal age, marriage/cohabitation, lower parity and non-
smoking. Almost half of women with pre-gestational diabetes
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and more than 30 % of mothers with epilepsy were reported as
supplement non-users.
Whenwe explored the associations between supplement use
and birth defects, we included live-born and stillborn infants in
the study population (n 894 927). Among them, 18 382 infants
had birth defects (2·1 %) and the majority of these infants had
isolated defects (n 17 391, 94·6 %). Among live-born infants,
18 117 were registered with birth defects (2·0 %), and among
stillbirths, the number was 265 (4·0 %). Table 3 shows the asso-
ciation between supplement use and infant birth defects, with
separate columns for isolated birth defects. Among infants of
mothers who used supplements, aRR was 0·94 (95 % CI 0·91,
0·98) and 0·95 (95 % CI 0·91, 0·99) for total and isolated birth
defects overall, respectively. Analysis stratified by year of birth
suggested that the inverse associations may be stronger in the
second time period (2006–2013) than in the first time period
(1999–2005) (online Supplementary Table S2). Supplement
use was associated with reduced risk of abdominal wall defects
(total aRR 0·58, 95 % CI 0·42, 0·80 and isolated aRR 0·58, 95 % CI
0·41, 0·84). Results for abdominal wall defects were similar when
the analysis was limited to folic acid only (Table 4) compared
with no supplement use (total aRR 0·50, 95 % CI 0·29, 0·84
and isolated aRR 0·45, 95 % CI 0·24, 0·83). Protective associations
were observed for both total and isolated gastroschisis and
omphalocele.
We observed an association between supplement use and
genital defects (total aRR 0·81, 95 % CI 0·72, 0·91 and isolated
aRR 0·76, 95 % CI 0·68, 0·86). Among genital defects, 88 % were
hypospadias (total hypospadias aRR 0·77, 95 % CI 0·68, 0·88 and
isolated hypospadias aRR 0·75, 95 % CI 0·65, 0·86). Multivitamin
use (not concurrent with folic acid) was not associated with
reduced risk of hypospadias (total hypospadias aRR 0·98,
95%CI 0·72, 1·33 and isolated hypospadias aRR1·03, 95%CI 0·76,
1·40). However, protective associations for hypospadias were
observed with folic acid only (total aRR 0·83, 95% CI 0·69, 0·99
and isolated 0·81, 95% CI 0·67, 0·98) and combined use of
folic acid and multivitamins (total aRR 0·65, 95% CI 0·53,
0·80 and isolated aRR 0·59, 95% CI 0·48, 0·74; Table 4).
Supplement use was also associated with reduced risk of
limb defects (total aRR 0·81, 95 % CI 0·74, 0·90), limb reduction
defects (total aRR 0·64, 95 %CI 0·45, 0·92) and clubfoot (total aRR
0·79, 95 % CI 0·67, 0·93). Nearly identical results were found for
isolated limb defects (Table 3). Use of multivitamins only, use of
folic acid only and folic acid combined with multivitamins were
associated with reduced risks for total and isolated limb defects
(Table 4). Numbers were small among those with limb reduction
defects that hadmothers who only usedmultivitamins. Folic acid
onlywas associatedwith reduced risks for limb reduction defects
(total aRR 0·50, 95 % CI 0·29, 0·88 and isolated aRR 0·48, 95 % CI
0·25, 0·89). For clubfoot, we observed that folic acid combined
Table 1. Major birth defects among 888 294 live births (birth defects, n 18 117), 6633 stillbirths (birth defects, n 265), and 2135 pregnancy terminations due to
fetal anomaly (TOPFA), Norway 1999–2013
(Relative risks and 95% confidence intervals; numbers and percentages)
Birth defects*
Prevalence per 10 000 Live births Stillbirths TOPFA Total






Isolated† Total Isolated†n % n % n %
Nervous system 17·9 17·1, 18·8 710 44·1 553 72 4·5 49 826 51·4 631 1608 1233
Neural tube defects 9·15 8·5, 9·8 229 27·9 189 41 5·0 29 551 67·1 457 821 675
Eye 2·79 2·4, 3·1 230 94·7 172 3 1·2 1 10 4·1 0 243 173
Ear, face and neck 2·41 2·1, 2·8 198 91·2 151 8 3·7 4 11 5·1 3 217 158
Heart defects 85·6 83·7, 87·6 7301 95·1 6783 46 0·6 31 334 4·4 211 7681 7025
Severe‡ 17·5 16·6, 18·4 1332 85·0 1176 14 0·9 13 221 14·1 167 1567 1356
Respiratory system 6·30 5·8, 6·9 429 75·8 295 34 6·0 17 103 18·2 25 566 337
Oral clefts 17·8 16·9, 18·7 1533 96·2 1378 23 1·4 10 38 2·4 5 1594 1393
Digestive system 14·5 13·7, 15·3 1128 86·8 840 25 1·9 8 147 11·3 28 1300 876
Oesophageal atresia 2·39 2·1, 2·7 204 94·9 135 2 0·9 1 9 4·2 0 215 136
Anorectal atresia 3·05 2·7, 3·4 217 79·2 134 5 1·8 0 52 19·0 0 274 134
Digestive other 6·82 6·3, 7·4 525 85·8 426 14 2·3 4 73 11·9 26 612 456
Abdominal wall defects 5·67 5·2, 6·2 333 65·4 285 44 8·6 28 132 25·9 46 509 359
Gastrochisis 2·99 2·7, 3·4 224 83·3 204 19 7·1 16 26 9·7 8 269 228
Omphalocele 2·00 1·7, 2·3 97 53·9 74 16 8·9 7 67 37·2 24 180 105
Urinary system 24·3 23·3, 25·3 1806 82·9 1546 26 1·2 12 347 15·9 183 2179 1741
Hydronephrosis 13·8 13·0, 14·5 1185 96·0 1087 3 0·2 1 46 3·7 23 1234 1111
Urinary other 10·5 9·9, 11·2 621 65·7 459 23 2·4 11 301 31·9 160 945 630
Genital organs 25·9 24·9, 27·0 2285 98·2 2282 14 0·60 10 28 1·2 2 2327 2294
Hypospadias 43·8 41·9, 45·8 2009 99·8 1854 2 0·1 0 0 0·0 0 2011 1856
Limb (without hip) 40·6 39·3, 41·9 3346 92·0 3093 63 1·7 36 230 6·3 50 3639 3179
Limb reduction 4·18 3·8, 4·6 284 75·7 238 15 4·0 6 76 20·3 16 375 260
Clubfoot 14·3 13·6, 15·1 1209 94·1 1137 22 1·7 16 54 4·2 12 1285 1165
Polydactyly and syndactyly 14·8 14·0, 15·6 1272 96·1 1183 14 1·1 7 38 2·9 3 1324 1193
*Birth defects were classified according to the EUROCAT (European Surveillance of Congenital Anomalies) classification system, https://eu-rd-platform.jrc.ec.europa.eu/sites/
default/files/appendices.pdf (hip anomalies not counted, chromosomal anomalies, genetic syndromes and microdeletions and teratogenic syndromes excluded).
† Cases with one or more birth defect(s) within the same organ-specific group and no birth defects in other organ-specific groups were classified as isolated.
‡ Severe cardiovascular defects included common arterial truncus (International Classification of Diseases-10 code Q200), double-outlet right ventricle (Q201), transposition of great
vessels (Q203), single ventricle (Q204), atrioventricular septal defect (Q212), tetralogy of Fallot (Q213), pulmonary valve atresia (Q220), tricuspid stenosis/atresia (Q224), Ebstein’s
anomaly (Q225), hypoplastic right heart (Q226), aortic valve stenosis/atresia (Q230), mitral valve anomalies (Q232–233), hypoplastic left heart (Q234), coarctation of aorta (Q251),
aortic atresia/interrupted aortic arch (Q252) and total anomalous pulmonary venous return (Q262).
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with multivitamins was associated with reduced risks for
clubfoot (total aRR 0·75, 95 % CI 0·58, 0·96 and isolated aRR
0·75, 95 % CI 0·58, 0·98; Table 4).
Finally, for urinary system defects, hydronephrosis amounted
65 % of the group. We found that use of folic acid was associated
with an increased risk for hydronephrosis (total aRR 1·21,
95 % CI 1·03, 1·42 and isolated aRR 1·22, 95 % CI 1·03, 1·44).
Use of folic acid combined with multivitamins showed the
strongest association (total aRR 1·33, 95 % CI 1·06, 1·66), while
the association was not present with multivitamins only
(Table 4). Stratification by time period showed that supplement
use was associated with an increased risk of hydronephrosis
in the first time period, but not in the second (online
Supplementary Table S2). Associations, albeit not statistically sig-
nificant, were observed for NTD, respiratory system defects and
digestive system defects. Analyses with supplement use during
pregnancy only showed protective associations for some birth
defects, including defects in the nervous system, abdominalwall,
genital organs and limbs (Table 3).
A total of 31 927 infants were from multiple pregnancies, and
among these, 1063 (3·3 %) had birth defects, while 17 319 (2·0 %)
of the singletons had birth defects. Excluding multiple births
Table 2. Maternal characteristics of 894 927 live- and stillborn infants according to folic acid and/or multivitamin supplement use before* and during
pregnancy, and during† pregnancy only, Norway 1999–2013
(Numbers and percentages)
Characteristics Total






n % n % n %
Total 894 927 386 012 43·1 192 951 21·6 315 964 35·3
Year of birth
1999 59 867 42 815 71·5 5375 9·0 11 677 19·5
2000 59 780 40 969 68·5 6264 10·5 12 547 21·0
2001 57 368 36 988 64·5 6745 11·7 13 635 23·8
2002 56 319 34 792 61·8 7041 12·5 14 486 25·7
2003 57 425 32 714 57·0 8854 15·4 15 857 27·6
2004 57 860 30 460 52·6 10 230 17·7 17 170 29·7
2005 57 594 27 761 48·2 11 445 19·9 18 388 31·9
2006 59 326 23 785 40·1 14 610 24·6 20 931 35·3
2007 59 290 18 594 31·4 17 141 28·9 23 555 39·7
2008 61 530 18 099 29·4 17 981 29·2 25 450 41·4
2009 63 048 17 130 27·2 18 565 29·5 27 353 43·4
2010 62 660 16 517 26·4 17 936 28·6 28 207 45·0
2011 61 373 15 584 25·4 17 163 28·0 28 626 46·6
2012 61 436 15 259 24·8 17 264 28·1 28 913 47·1
2013 60 051 14 545 24·2 16 337 27·1 29 169 48·6
Maternal age (years)
<20 19 817 11 434 57·7 1513 7·6 6870 34·7
20–24 130 742 62 848 48·1 17 790 13·6 50 104 38·3
25–29 288 824 122 897 42·6 59 675 20·7 106 252 36·8
30–34 297 129 122 989 41·4 72 738 24·5 101 402 34·1
35–39 134 256 55 382 41·3 34 950 26·0 43 924 32·7
≥40 24 074 10 405 43·2 6275 26·1 7394 30·7
Missing 85 57 67·1 10 11·8 18 21·2
Maternal smoking
No 626 575 228 803 36·5 156 111 24·9 241 661 38·6
Occasional 14 619 6335 43·3 2606 17·8 5678 38·8
Daily 107 553 55 524 51·6 14 002 13·0 38 027 35·4
Missing 146 180 93 350 65·2 20 232 13·8 30 598 20·9
Marital status
Married 427 039 187 763 44·0 98 326 23·0 140 950 33·0
Cohabitant 397 309 160 117 40·3 85 617 21·6 151 575 38·2
Single 59 677 30 972 51·9 7803 13·1 20 902 35·0
Other 10 902 7160 65·7 1205 11·1 2537 23·3
Parity
0 371 873 146 546 39·4 80 668 21·7 144 659 38·9
1 319 373 135 727 42·5 74 311 23·3 109 335 34·2
≥2 203 681 103 739 50·9 37 972 18·6 61 970 30·4
Pregestational diabetes
No 888 710 383 161 43·1 191 564 21·6 313 985 35·3
Yes 6217 2851 45·9 1387 22·3 1979 31·8
Epilepsy
No 888 405 383 806 43·2 191 104 21·5 313 495 35·3
Yes 6522 2206 33·8 1847 28·3 2469 37·9
*Folic acid and/or multivitamin supplement use before and during pregnancy (including 1·1% of the infants where mothers only used supplements before pregnancy.
† Folic acid and/or multivitamin supplement use during pregnancy only.
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Table 3. Unadjusted and adjusted* relative risks† (RR) for birth defects‡ among 888 294 live births (birth defects, n 18 117) and 6633 stillbirths (birth defects, n 265) by folic acid and/ormultivitamin supplement§
use, shown for eleven organ-specific birth defect groups with additional subgroups, based on EUROCAT|| definitions, Norway 1999–2013
(Relative risks and 95% confidence intervals; numbers and percentages)
Birth defects Supplement use Total birth defects Isolated birth defects
n %
Birth defects Unadjusted Adjusted Birth defects Unadjusted Adjusted
Supplement use n % RR 95% CI RR 95% CI n % RR 95% CI RR 95% CI
All births 894 927 100 18 382 2·05 17 391 1·94
No supplement use 386 012 43·1 8293 2·15 1 (Reference) 1 (Reference) 7833 2·03 1 (Reference) 1 (Reference)
Supplement use before and during 192 951 21·6 3740 1·94 0·90 0·86, 0·93 0·94 0·90, 0·98 3535 1·83 0·90 0·86, 0·93 0·95 0·91, 0·99
Supplement use only during 315 964 35·3 6349 2·01 0·93 0·90, 0·96 0·97 0·94, 1·01 6023 1·91 0·93 0·90, 0·97 0·99 0·95, 1·02
Nervous system 782 0·09 602 0·07
No supplement use 384 0·10 1 (Reference) 1 (Reference) 293 0·08 1 (Reference) 1 (Reference)
Supplement use before and during 163 0·08 0·85 0·70, 1·02 0·92 0·75, 1·13 126 0·07 0·86 0·70, 1·06 0·95 0·75, 1·19
Supplement use only during 235 0·07 0·74 0·63, 0·88 0·80 0·67, 0·96 183 0·06 0·76 0·63, 0·91 0·83 0·68, 1·02
Neural tube defects 270 0·03 218 0·02
No supplement use 142 0·04 1 (Reference) 1 (Reference) 108 0·03 1 (Reference) 1 (Reference)
Supplement use before and during 43 0·02 0·60 0·43, 0·85 0·73 0·50, 1·06 36 0·02 0·66 0·45, 0·97 0·84 0·56, 1·26
Supplement use only during 85 0·03 0·72 0·55, 0·95 0·86 0·63, 1·17 74 0·02 0·82 0·61, 1·11 1·03 0·74, 1·44
Eye 233 0·03 173 0·02
No supplement use 110 0·03 1 (Reference) 1 (Reference) 84 0·02 1 (Reference) 1 (Reference)
Supplement use before and during 45 0·02 0·82 0·58, 1·17 0·91 0·62, 1·33 34 0·02 0·81 0·54, 1·21 1·01 0·66, 1·56
Supplement use only during 78 0·02 0·86 0·64, 1·16 0·93 0·67, 1·28 55 0·02 0·79 0·55, 1·12 0·93 0·64, 1·37
Ear, face and neck 206 0·02 155 0·02
No supplement use 99 0·03 1 (Reference) 1 (Reference) 77 0·02 1 (Reference) 1 (Reference)
Supplement use before and during 36 0·02 0·73 0·50, 1·08 0·87 0·58, 1·30 24 0·01 0·62 0·39, 0·99 0·77 0·47, 1·26
Supplement use only during 71 0·02 0·89 0·65, 1·20 1·02 0·73, 1·41 54 0·02 0·86 0·60, 1·22 1·04 0·71, 1·53
Heart defects 7347 0·82 6814 0·76
No supplement use 3194 0·83 1 (Reference) 1 (Reference) 2970 0·77 1 (Reference) 1 (Reference)
Supplement use before and during 1563 0·81 0·97 0·92, 1·03 1·05 0·98, 1·12 1440 0·75 0·96 0·90, 1·03 1·05 0·98, 1·12
Supplement use only during 2590 0·82 0·99 0·94, 1·04 1·06 1·00, 1·12 2404 0·76 0·98 0·93, 1·04 1·07 1·01, 1·14
Severe heart defects 1346 0·15 1189 0·13
No supplement use 575 0·15 1 (Reference) 1 (Reference) 506 0·13 1 (Reference) 1 (Reference)
Supplement use before and during 300 0·16 1·03 0·90, 1·19 1·02 0·88, 1·18 266 0·14 1·04 0·89, 1·21 1·05 0·90, 1·22
Supplement use only during 471 0·15 1·00 0·88, 1·13 0·98 0·86, 1·11 417 0·13 1·00 0·88, 1·15 0·99 0·87, 1·14
Respiratory system 463 0·05 312 0·03
No supplement use 204 0·05 1 (Reference) 1 (Reference) 133 0·03 1 (Reference) 1 (Reference)
Supplement use before and during 92 0·05 0·91 0·71, 1·17 0·79 0·61, 1·03 69 0·04 1·03 0·77, 1·39 0·98 0·72, 1·34
Supplement use only during 167 0·05 1·00 0·82, 1·23 0·89 0·72, 1·10 110 0·03 1·00 0·77, 1·29 0·95 0·73, 1·24
Oral clefts 1556 0·17 1388 0·16
No supplement use 700 0·18 1 (Reference) 1 (Reference) 613 0·16 1 (Reference) 1 (Reference)
Supplement use before and during 318 0·16 0·90 0·79, 1·04 0·94 0·82, 1·08 293 0·15 0·95 0·83, 1·10 1·00 0·86, 1·16
Supplement use only during 538 0·17 0·94 0·84, 1·05 0·96 0·85, 1·08 482 0·15 0·96 0·85, 1·08 0·98 0·87, 1·12
Digestive system 1153 0·13 848 0·09
No supplement use 503 0·13 1 (Reference) 1 (Reference) 367 0·10 1 (Reference) 1 (Reference)
Supplement use before and during 235 0·12 0·93 0·79, 1·08 0·85 0·72, 1·00 169 0·09 0·91 0·76, 1·09 0·84 0·69, 1·02
Supplement use only during 415 0·13 1·01 0·89, 1·15 0·94 0·82, 1·08 312 0·10 1·04 0·89, 1·21 0·98 0·84, 1·15
Oesophageal atresia 206 0·02 136 0·02
No supplement use 94 0·02 1 (Reference) 1 (Reference) 61 0·02 1 (Reference) 1 (Reference)
Supplement use before and during 44 0·02 0·91 0·64, 1·32 0·84 0·56, 1·24 33 0·02 1·04 0·68, 1·60 0·94 0·58, 1·51
Supplement use only during 68 0·02 0·88 0·65, 1·21 0·83 0·60, 1·16 42 0·01 0·83 0·56, 1·24 0·77 0·51, 1·17
Anorectal atresia and stenosis 222 0·02 134 0·01
No supplement use 98 0·03 1 (Reference) 1 (Reference) 63 0·02 1 (Reference) 1 (Reference)
Supplement use before and during 42 0·02 0·86 0·59, 1·23 0·80 0·55, 1·17 23 0·01 0·72 0·45, 1·17 0·72 0·43, 1·20
Supplement use only during 82 0·03 1·02 0·76, 1·37 0·98 0·72, 1·33 48 0·02 0·92 0·63, 1·34 0·93 0·62, 1·38
Digestive other 539 0·06 430 0·05
No supplement use 236 0·06 1 (Reference) 1 (Reference) 187 0·05 1 (Reference) 1 (Reference)
Supplement use before and during 108 0·06 0·92 0·73, 1·15 0·83 0·66, 1·06 82 0·04 0·88 0·67, 1·14 0·80 0·61, 1·04
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Table 3. (Continued )
Birth defects Supplement use Total birth defects Isolated birth defects
n %
Birth defects Unadjusted Adjusted Birth defects Unadjusted Adjusted
Supplement use n % RR 95% CI RR 95% CI n % RR 95% CI RR 95% CI
Abdominal wall defects 377 0·04 313 0·03
No supplement use 188 0·05 1 (Reference) 1 (Reference) 151 0·04 1 (Reference) 1 (Reference)
Supplement use before and during 54 0·03 0·56 0·41, 0·77 0·58 0·42, 0·80 45 0·02 0·59 0·42, 0·82 0·58 0·41, 0·84
Supplement use only during 135 0·04 0·88 0·70, 1·01 0·75 0·59, 0·94 117 0·04 0·96 0·75, 1·22 0·79 0·61, 1·01
Gastroschisis 243 0·03 220 0·02
No supplement use 117 0·03 1 (Reference) 1 (Reference) 104 0·03 1 (Reference) 1 (Reference)
Supplement use before and during 37 0·02 0·61 0·42, 0·89 0·64 0·43, 0·95 33 0·02 0·61 0·41, 0·91 0·65 0·43, 0·99
Supplement use only during 89 0·03 0·93 0·70, 1·23 0·75 0·56, 0·99 83 0·03 0·97 0·73, 1·31 0·80 0·59, 1·07
Omphalocele 113 0·01 81 0·01
No supplement use 61 0·02 1 (Reference) 1 (Reference) 42 0·01 1 (Reference) 1 (Reference)
Supplement use before and during 15 0·01 0·48 0·26, 0·88 0·47 0·25, 0·86 11 0·01 0·52 0·26, 1·01 0·45 0·22, 0·92
Supplement use only during 37 0·01 0·76 0·49, 1·17 0·68 0·44, 1·05 28 0·01 0·81 0·50, 1·30 0·67 0·40, 1·11
Urinary system 1832 0·20 1558 0·17
No supplement use 761 0·20 1 (Reference) 1 (Reference) 638 0·17 1 (Reference) 1 (Reference)
Supplement use before and during 419 0·22 1·09 0·97, 1·23 1·11 0·98, 1·26 354 0·18 1·10 0·96, 1·25 1·14 0·99, 1·32
Supplement use only during 652 0·21 1·04 0·94, 1·16 1·07 0·96, 1·20 566 0·18 1·08 0·96, 1·21 1·13 1·00, 1·28
Hydronephrosis 1188 0·13 1088 0·12
No supplement use 477 0·12 1 (Reference) 1 (Reference) 438 0·11 1 (Reference) 1 (Reference)
Supplement use before and during 283 0·15 1·18 1·02, 1·37 1·21 1·03, 1·42 257 0·13 1·16 1·00, 1·36 1·22 1·03, 1·44
Supplement use only during 428 0·14 1·09 0·96, 1·24 1·13 0·98, 1·31 393 0·12 1·09 0·95, 1·25 1·15 0·99, 1·33
Urinary other 644 0·07 470 0·05
No supplement use 284 0·07 1 (Reference) 1 (Reference) 200 0·05 1 (Reference) 1 (Reference)
Supplement use before and during 136 0·07 0·94 0·77, 1·16 0·94 0·75, 1·18 97 0·05 0·95 0·75, 1·22 0·98 0·75, 1·29
Supplement use only during 224 0·07 0·96 0·80, 1·14 0·97 0·80, 1·17 173 0·05 1·05 0·86, 1·29 1·10 0·88, 1·37
Genital organs 2299 0·26 2292 0·26
No supplement use 1061 0·27 1 (Reference) 1 (Reference) 1095 0·28 1 (Reference) 1 (Reference)
Supplement use before and during 426 0·22 0·80 0·71, 0·89 0·81 0·72, 0·91 412 0·21 0·75 0·67, 0·84 0·76 0·68, 0·86
Supplement use only during 812 0·26 0·93 0·85, 1·02 0·94 0·85, 1·04 785 0·25 0·87 0·79, 0·95 0·90 0·81, 0·99
Hypospadias 459 084 100 2011 0·44 1856 0·40
No supplement use 197 928 43·1 936 0·47 1 (Reference) 1 (Reference) 873 0·44 1 (Reference) 1 (Reference)
Supplement use before and during 98 875 21·5 366 0·37 0·78 0·69, 0·88 0·77 0·68, 0·88 329 0·33 0·75 0·66, 0·85 0·75 0·65, 0·86
Supplement use only during 162 281 35·4 709 0·44 0·92 0·83, 1·02 0·92 0·83, 1·03 654 0·40 0·91 0·82, 1·01 0·92 0·82, 1·03
Limb (without hip) 3409 0·38 3129 0·35
No supplement use 1678 0·43 1 (Reference) 1 (Reference) 1530 0·40 1 (Reference) 1 (Reference)
Supplement use before and during 646 0·33 0·76 0·70, 0·84 0·81 0·74, 0·90 601 0·31 0·78 0·71, 0·86 0·84 0·76, 0·93
Supplement use only during 1085 0·34 0·78 0·72, 0·84 0·82 0·76, 0·90 998 0·32 0·79 0·73, 0·85 0·84 0·77, 0·92
Limb reduction defects 299 0·03 244 0·03
No supplement use 152 0·04 1 (Reference) 1 (Reference) 125 0·03 1 (Reference) 1 (Reference)
Supplement use before and during 51 0·03 0·67 0·48, 0·92 0·64 0·45, 0·92 42 0·02 0·66 0·47, 0·94 0·64 0·43, 0·94
Supplement use only during 96 0·03 0·76 0·59, 0·99 0·73 0·55, 0·96 77 0·02 0·74 0·56, 0·99 0·71 0·53, 0·97
Clubfoot talipes equinovarus 1231 0·14 1153 0·13
No supplement use 598 0·15 1 (Reference) 1 (Reference) 560 0·15 1 (Reference) 1 (Reference)
Supplement use before and during 221 0·11 0·73 0·63, 0·85 0·79 0·67, 0·93 210 0·11 0·74 0·63, 0·87 0·81 0·69, 0·96
Supplement use only during 412 0·13 0·83 0·73, 0·94 0·87 0·76, 0·99 383 0·12 0·82 0·72, 0·94 0·87 0·76, 1·00
Polydactyly and syndactyly 1286 0·14 1190 0·13
No supplement use 626 0·16 1 (Reference) 1 (Reference) 575 0·15 1 (Reference) 1 (Reference)
Supplement use before and during 256 0·13 0·81 0·70, 0·94 0·87 0·75, 1·03 240 0·12 0·83 0·71, 0·97 0·90 0·77, 1·06
Supplement use only during 404 0·13 0·78 0·69, 0·89 0·85 0·74, 0·98 375 0·12 0·79 0·69, 0·90 0·87 0·75, 1·00
*Adjusted for the following: year of birth, maternal age, marital status, parity, maternal smoking habits at the beginning of pregnancy, pregestational diabetes and maternal epilepsy.
† Relative risks compared with infants of supplement non-users (Reference group), relative risk calculated as the ratio of birth prevalence in the exposed group and the birth prevalence in the unexposed group.
‡ Cases with one or more birth defect(s) within the same organ-specific group and no other organ affected were classified as isolated.
§ Vitamin supplement use: folic acid and/or multivitamins before and during pregnancy (including 1.1% of the infants where mothers only used vitamins before pregnancy) and during pregnancy only.










Downloaded from https://www.cambridge.org/core. Norwegian Institute of Public Health, on 20 Feb 2021 at 21:20:33, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114520001178
Table 4. Adjusted* relative risks† (aRR) for birth defects‡ by different vitamin supplement exposure§ categories among 894 927 live births and stillbirths, birth defect groups based on EUROCAT||definitions,
Norway 1999–2013
(Numbers and percentages; adjusted relative risks and 95% confidence intervals)
Vitamin supplement exposure categories (%)
Multivitamins only Folic acid only Folic acid and multivitamins
Supplement use n % n % n %
No use 386 012 43·1 386 012 43·1 386 012 43·1
Use before and during 19 022 2·1 73 042 8·2 66 560 7·5
Other combinations of use 489 893 54·8 435 873 48·7 442 355 49·4
Birth defect Supplement use
No. of birth
defects aRR 95% CI
No. of birth
defects aRR 95% CI
No. of birth
defects aRR 95% CI
Total
Abdominal wall defects No use 188 1 (Reference) 188 1 (Reference) 188 1 (Reference)
Use before and during 6 0·66 0·29, 1·49 17 0·50 0·29, 0·84 20 0·67 0·42, 1·09
Other combination 183 0·70 0·56, 0·88 172 0·74 0·59, 0·92 169 0·71 0·57, 0·89
Gastroschisis No use 117 1 (Reference) 117 1 (Reference) 117 1 (Reference)
Use before and during 4 0·67 0·25, 1·82 11 0·51 0·26, 1·00 12 0·67 0·36, 1·23
Other combination 122 0·71 0·54, 0·94 115 0·75 0·57, 0·99 114 0·74 0·56, 0·96
Omphalocele No use 61 1 (Reference) 61 1 (Reference) 61 1 (Reference)
Use before and during 2 0·67 0·16, 2·78 5 0·42 0·16, 1·11 7 0·66 0·29, 1·51
Other combination 50 0·63 0·41, 0·96 47 0·65 0·43, 0·99 45 0·62 0·40, 0·94
Isolated
Abdominal wall defects No use 151 1 (Reference) 151 1 (Reference) 151 1 (Reference)
Use before and during 6 0·80 0·35, 1·82 13 0·45 0·24, 0·83 17 0·69 0·41, 1·16
Other combination 156 0·72 0·56, 0·91 149 0·76 0·60, 0·97 145 0·73 0·58, 0·94
Gastroschisis No use 104 1 (Reference) 104 1 (Reference) 104 1 (Reference)
Use before and during 4 0·75 0·28, 2·04 10 0·52 0·25, 1·05 11 0·68 0·36, 1·29
Other combination 112 0·73 0·55, 0·97 106 0·78 0·59, 1·03 105 0·76 0·57, 1·00
Omphalocele No use 42 1 (Reference) 42 1 (Reference) 42 1 (Reference)
Use before and during 2 0·97 0·23, 4·04 3 0·33 0·09, 1·14 5 0·62 0·23, 1·62
Other combination 37 0·60 0·37, 0·99 36 0·66 0·40, 1·07 34 0·61 0·37, 1·01
Total
Urinary system No use 761 1 (Reference) 761 1 (Reference) 761 1 (Reference)
Use before and during 41 1·06 0·76, 1·48 165 1·15 0·97, 1·38 157 1·20 1·00, 1·44
Other combination 1030 1·08 0·98, 1·20 906 1·07 0·96, 1·19 914 1·07 0·96, 1·19
Hydronephrosis No use 477 1 (Reference) 477 1 (Reference) 477 1 (Reference)
Use before and during 22 0·87 0·56, 1·37 111 1·26 1·01, 1·57 107 1·33 1·06, 1·66
Other combination 689 1·18 1·03, 1·34 600 1·15 1·00, 1·31 604 1·14 1·00, 1·30
Urinary other No use 284 1 (Reference) 284 1 (Reference) 284 1 (Reference)
Use before and during 19 1·38 0·84, 2·25 54 0·96 0·72, 1·30 50 0·98 0·71, 1·35
Other combination 341 0·93 0·78, 1·11 306 0·95 0·80, 1·13 310 0·95 0·80, 1·13
Isolated
Urinary system No use 638 1 (Reference) 638 1 (Reference) 638 1 (Reference)
Use before and during 33 1·04 0·72, 1·51 145 1·23 1·02, 1·49 131 1·22 1·00, 1·49
Other combination 887 1·14 1·01, 1·27 775 1·12 0·99, 1·25 789 1·12 1·00, 1·26
Hydronephrosis No use 438 1 (Reference) 438 1 (Reference) 438 1 (Reference)
Use before and during 21 0·95 0·61, 1·50 104 1·30 1·04, 1·63 95 1·31 1·04, 1·66
Other combination 629 1·18 1·03, 1·36 546 1·15 1·00, 1·32 555 1·15 1·00, 1·33
Urinary other No use 200 1 (Reference) 200 1 (Reference) 200 1 (Reference)
Use before and during 12 1·24 0·66, 2·32 41 1·07 0·75, 1·54 36 1·02 0·69, 1·49
Other combination 258 1·03 0·84, 1·27 229 1·04 0·84, 1·28 234 1·04 0·85, 1·29
Total
Genital organs No use 1061 1 (Reference) 1061 1 (Reference) 1061 1 (Reference)
Use before and during 51 1·00 0·75, 1·32 168 0·85 0·72, 1·01 131 0·71 0·54, 0·79
Other combination 1187 0·88 0·80, 0·97 1070 0·90 0·82, 0·99 1107 0·92 0·83, 1·01
Hypospadias No use 936 1 (Reference) 936 1 (Reference) 936 1 (Reference)
Use before and during 45 0·98 0·72, 1·33 146 0·83 0·69, 0·99 108 0·65 0·53, 0·80
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Table 4. (Continued )
Vitamin supplement exposure categories (%)
Multivitamins only Folic acid only Folic acid and multivitamins
Birth defect Supplement use
No. of birth
defects aRR 95% CI
No. of birth
defects aRR 95% CI
No. of birth
defects aRR 95% CI
Isolated
Genital organs No use 1095 1 (Reference) 1095 1 (Reference) 1095 1 (Reference)
Use before and during 51 0·97 0·73, 1·30 164 0·81 0·68, 0·96 123 0·65 0·54, 0·79
Other combination 1146 0·83 0·76, 0·92 1033 0·85 0·77, 0·93 1074 0·87 0·79, 0·96
Hypospadias No use 873 1 (Reference) 873 1 (Reference) 873 1 (Reference)
Use before and during 44 1·03 0·76, 1·40 133 0·81 0·67, 0·98 92 0·59 0·48, 0·74
Other combination 939 0·84 0·76, 0·94 850 0·86 0·77, 0·95 891 0·89 0·80, 0·98
Total
Limb No use 1678 1 (Reference) 1678 1 (Reference) 1678 1 (Reference)
Use before and during 56 0·70 0·53, 0·91 250 0·85 0·74, 0·98 218 0·80 0·69, 0·93
Other combination 1675 0·83 0·77, 0·90 1481 0·82 0·76, 0·89 1513 0·83 0·76, 0·89
Limb reduction defects No use 152 1 (Reference) 152 1 (Reference) 152 1 (Reference)
Use before and during 2 0·26 0·06, 1·07 15 0·50 0·29, 0·88 25 0·93 0·59, 1·46
Other combination 145 0·71 0·55, 0·93 132 0·73 0·56, 0·95 122 0·67 0·51, 0·88
Clubfoot No use 607 1 (Reference) 607 1 (Reference) 607 1 (Reference)
Use before and during 25 0·85 0·57, 1·27 87 0·83 0·66, 1·05 72 0·75 0·58, 0·96
Other combination 612 0·84 0·74, 0·96 550 0·84 0·74, 0·95 565 0·85 0·75, 0·96
Polydactyly and syndactyly No use 626 1 (Reference) 626 1 (Reference) 626 1 (Reference)
Use before and during 22 0·76 0·49, 1·17 98 0·91 0·73, 1·14 86 0·86 0·68, 1·09
Other combination 638 0·88 0·77, 1·00 562 0·87 0·76, 0·98 574 0·87 0·77, 0·99
Isolated
Limb No use 1530 1 (Reference) 1530 1 (Reference) 1530 1 (Reference)
Use before and during 55 0·75 0·57, 0·99 235 0·88 0·76, 1·02 199 0·81 0·70, 0·95
Other combination 1544 0·85 0·78, 0·92 1364 0·83 0·77, 0·90 1400 0·84 0·78, 0·91
Limb reduction defects No use 125 1 (Reference) 125 1 (Reference) 125 1 (Reference)
Use before and during 2 0·32 0·08, 1·28 12 0·48 0·25, 0·89 21 0·92 0·56, 1·51
Other combination 117 0·70 0·52, 0·93 107 0·72 0·54, 0·95 98 0·65 0·48, 0·87
Clubfoot No use 560 1 (Reference) 560 1 (Reference) 560 1 (Reference)
Use before and during 25 0·93 0·62, 1·38 81 0·85 0·67, 1·08 66 0·75 0·58, 0·98
Other combination 568 0·86 0·75, 0·97 512 0·85 0·75, 0·97 527 0·86 0·76, 0·98
Polydactyly and syndactyly No use 575 1 (Reference) 575 1 (Reference) 575 1 (Reference)
Use before and during 21 0·80 0·51, 1·23 95 0·97 0·77, 1·22 80 0·89 0·70, 1·13
Other combination 594 0·90 0·79, 1·03 520 0·88 0·77, 1·00 535 0·89 0·78, 1·02
*Adjusted for the following: year of birth, maternal age, marital status, parity, maternal smoking habits at the beginning of pregnancy, pregestational diabetes and maternal epilepsy.
† Relative risks compared with infants of supplement non-users, relative risk calculated as the ratio of birth prevalence in the exposed group and the birth prevalence in the unexposed group (Reference group).
‡ Cases with one or more birth defect(s) within the same organ-specific group and no other organ affected were classified as isolated.
§ Supplement use: multivitamins before and during pregnancy, folic acid before and during pregnancy, or combined use of multivitamins and folic acid before and during pregnancy, other combination of supplement use: remaining groups of
supplement use.
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from the analysis did not affect the results much (online
Supplementary Table S3). However, infants in multiple births
had increased risk of total birth defects compared with single-
tons, RR 1·63 (95 %CI 1·55, 1·76). Yet, mothers of infants inmulti-
ple births used supplements before and during pregnancy
slightly more than did mothers of singletons (25·6 and 21·4 %,
respectively). The percentage of IVF among mothers with
multiple births was 21·6 % compared with 2·0 % among mothers
with singletons. Among all infants with birth defects (n 18 382),
3·6 % of them were from IVF (n 666). Infants from IVF pregnan-
cies had an increased risk of total birth defects compared with
naturally conceived infants (RR 1·33, 95 % CI 1·23, 1·44).
Discussion
The present study included eleven major non-chromosomal
birth defect groups in the entire birth population of Norway
during 1999–2013. The study found that folic acid and/or
multivitamin supplement use before and during pregnancy
was associated with a slight reduction in risk of infant total birth
defects among live- and stillborn babies (aRR 0·94, 95 % CI 0·91,
0·98). The reduced risk was observed for birth defects in the
abdominalwall, genital organs and limbs. Protective associations
were also suggested for NTD, respiratory system defects
and digestive system defects although CI included the null
value of 1.
Mothers who smoked, who were younger, single or had
higher parity were less likely to use folic acid supplements
before and during pregnancy (Table 2). These factors could
be related to a lack of pregnancy planning(25). The rates of
unplanned pregnancies in Norway are unknown, but in a large
Norwegian cohort, 20 % reported that they had not planned the
pregnancy(26). Folate depletion increases if inter-pregnancy
intervals are short(27), and we found that higher parity was
associated with less use of supplements. Because of increased
requirements of folate throughout pregnancy, depletion could
result in an increased risk of birth defects in the subsequent
neonate(28). Also, research has indicated that folate levels are
lower in pregnant smokers than in non-smokers(29), and fetuses
of pregnant smokers could possibly benefit from higher doses of
folic acid. Still, we observed that smoking mothers used less folic
acid supplements than non-smokers did (Table 2). This may be
related to an educational gradient in smoking habits(30). Nearly
half of women with pregestational diabetes were defined as
supplement non-users. This is probably partly due to missing
data from the hospitals but could also be related to unplanned
pregnancies. Research has indicated that folic acid use may be
even more important in women with pregestational diabetes
to prevent birth defects(31,32).
Comparison with previous studies
We have previously examined the relationship between folic
acid or multivitamin supplement use and infant NTD(33), oral
clefts(34) and heart defects(35) from the same source population
(MBRN). There were several differences between the previous
three studies and the current one. For example, the current paper
separates total and isolated NTD. More than 20 % of infants with
NTD had associated anomalies. We observed associations
between supplement use and some of the anomalies that
co-occurred with NTD (limbs, urinary, digestive defects,
abdominal wall defects). Yet, the association measures were
nearly identical for total and isolated NTD. A 2015 Cochrane
review assessed the effects of folic acid supplementation on birth
defects(19) and concluded that folic acid, alone or in combination
with vitamins and minerals, prevents NTD, with high-quality
evidence according to Grades of Recommendation
Assessment, Development and Evaluation (GRADE) criteria(36).
However, there was insufficient evidence for other birth defects,
motivating efforts to quantify the associations between use of
folic acid and birth defects other than NTD(37). Supplement
use was inversely associated with several of the birth defects that
co-occurred with oral clefts. A 2018 systematic review from
observational studies concluded that folic acid supplementation
reduced the risk of non-syndromic oral clefts(38), whereas in the
2015 Cochrane report, there were insufficient data from rando-
mised controlled trials to evaluate the effects on oral clefts(19).
The association between folic acid and multivitamin supple-
ment use and congenital heart defects has been reported in
similar studies from Norway and Denmark(20,35). In the study
by Leirgul et al.(35), individuals with heart defects were identified
from four data sources, including MBRN, whereas the present
study used data from the MBRN updated with additional 4 years.
Yet, the finding in the present study (aRR 1·05, 95 %CI 0·98, 1·12)
was similar to the previous paper (aRR 1·10, 95 % CI 1·03, 1·16).
Further, in two national birth cohorts in Norway and Denmark,
with prospective data from nearly 200 000 births and 2247 indi-
viduals with heart defects, folic acid supplement use was not
associated with heart defects (aRR 0·99, 95 % CI 0·80, 1·22)(20).
These findings were also in accordance with the Cochrane
review from 2015(19), albeit with low-quality evidence according
to GRADE.
In our study, use of folic acid or multivitamins was associated
with a reduced risk of abdominal wall defects, including both
gastroschisis and omphalocele. This corresponds well with the
literature(39–41), although there are exceptions(42,43).
Use of folic acid supplements before and during pregnancy
was associated with reduced risk of infant hypospadias in our
study, but we did not observe associations with multivitamins
(Table 4). A Hungarian case–control study suggested a dose-
dependent relationship between folic acid supplement use
and risk for infant hypospadias(44). The folic acid doses were
considerably higher than in our study, and however, our findings
suggested similar associations. In a systematic review by Goh
et al., no associations between multivitamin supplements and
hypospadias were found from the selected cohort studies and
randomised controlled trials(45).
We observed that the use of multivitamins and/or folic acid
was associated with reduced risk of limb defects, with the largest
risk reduction for the limb reduction subgroup (Table 3). Several
studies have shown similar results, with risk reductions of about
one-third(46,47). However, the quality of the evidence has not
been convincing. We found a non-significant, but somewhat
lower point estimate for limb reduction defects among infants
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of mothers using multivitamins only than among infants of folic
acid only users (Table 4). The association nearly disappeared for
use of folic acid combined with multivitamins. There was limited
power to detect associations due to the small number of infants
in the multivitamin group. In contrast to limb reduction defects,
we found that the use of folic acid combined with multivitamins
was associated with a reduced risk of infant clubfoot, while
multivitamin use was not. One study has found that elevated
plasma homocysteine levels were associated with increased risk
of clubfoot(48), which suggest that folate insufficiency contributes
to the risk.
Use of folic acid supplements was associated with an
increased risk of urinary system defects, mainly driven by the
large proportion of infants with hydronephrosis in this category.
This corresponds well with the literature(42,49,50). However, the
association was not present for infants where mothers used
multivitamins only, which does not correspond with previous
findings(17,47). According to EUROCAT, there are discrepancies
in diagnostic criteria for hydronephrosis cases(51), and registra-
tion of hydronephrosis is recommended only if the renal pelvis
is 10 mm or more after birth, while the MBRN does not specify
this distinction. Further, the ascertainment of hydronephrosis
in the MBRN may be lower than that of birth defects that are
visible after birth.
Study strengths and limitations
Major strengths of our study include the prospective design as
well as the large study population of almost 900 000 infants, with
detailed information on maternal periconceptional supplement
use, more than 18 000 infants with birth defects, and information
on several potential confounders.With a study of thismagnitude,
the effect size across all birth defects may be highly statistically
significant even if associated with small deviations of the relative
risk from 1. For example, it is possible to detect a 10 % risk
reduction of a rare event, which may seem small at the level
of the individual if the focus is on the clinical importance of
the prevention strategy. One should bear in mind, however, that
a small relative risk may have an important impact from a public
health perspective.
Our study had some limitations. First, misclassification of
exposure may have biased the association measures. The expo-
sure information was in most cases gathered early in pregnancy,
which reduces the risk of maternal recall bias, because mothers
do not know at this point the birth defect status of their babies.
Errors in reporting by the hospitals concerning supplement type
and timing may have occurred. The group of non-users was a
mixture of mothers who did not use supplements and mothers
where the hospitals did not report the use (missing). This non-
differential misclassification of the exposure is considered to
be present and could have biased the association measures
towards the null. According to a recent study from theMBRN that
explored the epidemiology of limb reduction defects, including
their relationwithmaternal use of folic acid/multivitamin supple-
ments, approximately 12 % of all births (excluding TOPFA) had
missing information on folic acid and multivitamin supplement
use during 1999–2016(52). When multiple imputation was
applied to handle missing data on folic acid and multivitamin
supplement use, the estimate was close to our finding for limb
reduction defects (aRR 0·7, 95 % CI 0·6, 0·9)(52).
There is a risk of misclassification of birth defects in the
MBRN, with varying ascertainment for the different defects.
Validation studies have been performed for certain birth defects
(oral clefts(53), gastroschisis(54) andDown syndrome(55)) showing
satisfactory results. However, for oral clefts, the ascertainment
depended on the visibility and severity of the cleft, indicating that
some birth defects may be under-reported to the MBRN. For
example, it is likely that the diagnosis of hydronephrosis
reported to the MBRN depends on a prenatal diagnosis by ultra-
sound, and many women only have the routine ultrasound
around 18 gestational weeks.
Second, the lack of information on supplement use in TOPFA
could have introduced selection bias. If women who terminated
a pregnancy for a birth defect were less likely to use folic acid,
the associations would be underestimated. However, if women
who used folic acid were more likely to opt for a termination of
pregnancy due to birth defects, it would bias the risk ratio
towards the null. This situation could be plausible if increased
folic acid supplement use was associated with better prenatal
care, which in turn could be associated with a prenatal diagnosis
of birth defects. However, in Norway, prenatal screening with
ultrasound is free of charge and offered to all pregnant women
at 18 gestational weeks or earlier for women with a high-risk
pregnancy. Therefore, such differential bias is not likely.
Except for nervous system defects (51·4 % TOPFA) and ompha-
locele (37·2 %), most pregnancies affected by the described birth
defects were continued to delivery. Selection bias is thus mostly
a concern for the association between supplement use and NTD
and omphalocele.Womenwho use IVF aremore likely to have a
multiple gestations and are, by definition, pregnancy planners
and therefore much more likely to use folic acid(56). Birth defects
occur more frequently in infants from IVF(57) and multiple(23)
pregnancies as compared with naturally conceived infants and
singletons. However, birth defects from IVF pregnancies only
accounted for 3·6 % of total birth defects, and the associations
were nearly unchanged in analyses restricted to singletons.
Thus, selection bias due to IVF and multiple gestations could
be ruled out.
Third, we were able to adjust for a priori selected confound-
ers known to be associated with birth defects and supplement
use. Adjustment did not change the estimates much. However,
stratification by time period showed that from 2006 onwards,
associations were stronger for some defects. A possible explan-
ation for this finding could be that more women complied with
the recommendations in the latest time period. The reported
prevalence of supplement use before and during pregnancy
in the two time periods was 13·8 % (1999–2005) and 28 %
(2006–2013). Analyses conditioned on complete smoking infor-
mation produced similar results as when assigning missing to a
separate category. Adjusting for year of birth slightly weakened
the associationmeasure (aRR total birth defectswithout adjusting
for year of birth: 0·90, 95 % CI 0·87, 0·94), possibly due to
differences in the prevalence of supplement use, and natural
variations in outcome prevalence over the study period. The
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observed associations in our study could be due to unmeasured
confounding. We had no information on maternal BMI(58) or
baseline diet(59).
The exact mechanism of why folic acid supplementation
prevents NTD or other birth defects is not known, but
associations have been established with erythrocyte folate
concentration(60). Women below the cut-off for what is consid-
ered optimal erythrocyte are thought to have elevated risk of
having babies with NTD(61). Folate functions as a coenzyme in
one-carbon metabolism during the methylation cycle and is
crucial for DNA synthesis, and during pregnancy, there are
higher rates of one-carbon transfer reactions(4). The randomised
controlled trials establishing a preventive role for NTDwere spe-
cific to folic acid. Dietary folate is less bioavailable than folic acid,
and consumption of dietary folates is considered to result in a
significantly smaller increase in erythrocyte folate concentration
than folic acid(62,63). Since food fortification with folic acid is not
mandatory in Norway, the prevention strategy with a supple-
mentation programme requires a high proportion of planned
pregnancies and high compliance with the programme. Many
Norwegian women are not aware of the importance of supple-
mentation before pregnancy and have diets that do not meet the
recommendations. According to MBRN online statistics (http://
statistikkbank.fhi.no/mfr/), maternal use of folic acid supple-
ments before pregnancy was reported for around a third of
infants in 2018. The proportion of women who use folic acid
supplements before conception is even lower in some sub-
groups of the population(64). Since the prevalence of folic acid
supplement use remains low, efforts to increase supplement
compliance are needed.
Our findings suggest that some birth defects may be
prevented by maternal use of folic acid or multivitamins, but that
the extent of the risk reduction differs for the different types of
birth defects and type of exposure (multivitamin or folic acid).
Better definitions of the exposures regarding specific supple-
ment types, timing and dosage would be beneficial in under-
standing the different roles of specific micronutrients in the
aetiology of birth defects. Thus, in unplanned pregnancies, even
though the time window to prevent NTD is closed, initialising
supplementation during pregnancy could be beneficial to
reduce defects that occur later in the first trimester. Since our
study suggests that folic acid or multivitamin supplementation
could have protective associations for other birth defects besides
NTD, the prevention potential may be larger than anticipated.
With an annual birth rate of nearly 60 000 and a birth defect
prevalence of about 2 %, folic acid supplements used by the
40 000 women reported as non-users could prevent birth defects
in nearly fifty infants annually in Norway, assuming the protec-
tive associations of 6 % risk reduction in our study were causal.
In conclusion, use of folic acid and/or multivitamin supple-
ments before and during pregnancy was associated with a small
reduction in the risk of total birth defects among live births and
stillbirths. More specifically, the risk reduction was observed for
abdominal wall defects, genital defects and limb defects. Folic
acid supplement use was associated with increased risk for
hydronephrosis. Protective associations were suggested for
supplement use and NTD, respiratory system defects and diges-
tive system defects although CI included the null value of 1.
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